Vertex Planning NDA Filing for CF Drug in Patients with G551D Mutations for Second Half of 2011

After data from a Phase III trial yielded significant improvements in the lung function of study participants who received the investigational drug VX-770, Vertex said it would work with regulatory agencies in the US and abroad to speed the drug's approval.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.